Blog

November 17, 2014April 24, 2018

Johnson & Johnson Vision Care, Inc., introduces a new innovation in beauty

The company just recently launched a new category of contact lenses that enhance natural beauty while helping to support healthy eyes.

1-DAY ACUVUE® DEFINE™ with LACREON® Technology lens is now available at a limited number of eye care professionals’ practices in Canada and the United States, with expanded product availability expected in the first half of 2015.

1-DAY ACUVUE® DEFINE™ Brand offers three variants of iris-inspired innovative designs to give the eye greater definition by creating contrast, and to add depth and definition to the iris without changing the eye’s natural colour and allowing it to shine through.

1-DAY ACUVUE® DEFINE™ Brand will be available in plano and vision correction ranges from +1.00 to -9.00 with a base curve of 8.5 and diameter of 14.2 mm.

For further information: https://www.optiknow.ca/wp-content/uploads/2014/11/JnJ_1DAYACUVUEDEFINEINITIALLAUNCH_ECPPRESSRELEASE_FINAL-NOV10.pdf

November 17, 2014April 24, 2018

Actavis to acquire Allergan

Actavis and Allergan announced that they have entered into a definitive agreement under which Actavis will acquire Allergan.

Actavis will pay $129.22 US in cash plus Actavis shares for each share of Allergan common stock. Based on the closing price of Actavis shares on November 14, 2014, the transaction is valued at approximately $66 billion, or $219 per Allergan share.

The transaction has been unanimously approved by the boards of directors of both companies and is supported by the two management teams. This consequently puts an end to Valeant’s attempt to take over Allergan that began several months ago and about which much has been written.

The two companies combined will create one of the top 10 global growth pharmaceuticals with expected revenue of $23 billion in 2015. This deal should close in the second quarter of 2015.

For further details on the transaction: http://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=883356

November 14, 2014April 24, 2018

Appointments at OSI

Optometric Services Inc. (OSI) has announced the appointment of Karina Dandavino as the director of marketing.

New to the position, Dandavino’s duties now consist of managing all marketing activities for the company and its subsidiaries.

Dandavino has been a member of the OSI team since 2002 and held a number of positions. Before her recent appointment, she had been assistant director of marketing since 2008.

Given her years of experience within the company, she has acquired a thorough understanding of the optometry industry in Canada. Furthermore, she was a veteran of the fashion world prior to joining OSI.

OSI has also announced that Steve Bélanger, formerly director of marketing accounts at OSI, will step into the position of assistant director of marketing.

For further information, click HERE (French text only)

November 14, 2014April 24, 2018

New Christian Lacroix collection

Mondottica’s new Christian Lacroix collection features quilted-texture leather inserts in metal or exclusive Mazzuchelli laminated acetates. The season’s iconic prints are transferred onto acetate and covered in rich colours. Models: CL3040, CL1048, CL1051 and CL1052. Distributed by Centennial Optical. www.centennialoptical.com

November 14, 2014April 24, 2018

University of Waterloo develops new treatment for dry eyes

Scientists from the University of Waterloo have developed a nanoparticle-based topical solution to combat dry eyes with a single weekly application.

Patients currently have to administer a solution three times a day to reduce pain and irritation. The solution developed at the University of Waterloo gradually delivers the correct amount of drug-infused nanoparticules to the surface of the eyeball over a period of five days before the body metabolizes them.

One weekly dose replaces 15 doses or more of the traditional treatments. The substance causes no irritation. If clinical trials are conclusive, this therapy could be available on the market within five years.

For further information: http://link.springer.com/article/10.1007/s12274-014-0547-3#page-1